Your fact-checks will appear here
Clinical trials examining the efficacy of Abemaciclib in treating cancer.
Real-world multicenter data from the find (rwPFS) than palbociclib overall and show ribociclib (along with abemaciclib) outperforming palbociclib in specific subgroups — notably premenopausal patients...
each carry subgroup data from randomized trials and growing real-world cohorts that examine visceral vs non‑visceral disease, endocrine‑sensitivity, menopausal status, molecular subtype (e.g., luminal...
’s evidence base for improving progression‑free survival (PFS) is strong and consistent: randomized phase III trials demonstrated statistically significant PFS benefit versus endocrine therapy alone, ...